ES2874592T3 - Tratamiento de la infección por el virus de la hepatitis delta con interferón lambda - Google Patents
Tratamiento de la infección por el virus de la hepatitis delta con interferón lambda Download PDFInfo
- Publication number
- ES2874592T3 ES2874592T3 ES17753966T ES17753966T ES2874592T3 ES 2874592 T3 ES2874592 T3 ES 2874592T3 ES 17753966 T ES17753966 T ES 17753966T ES 17753966 T ES17753966 T ES 17753966T ES 2874592 T3 ES2874592 T3 ES 2874592T3
- Authority
- ES
- Spain
- Prior art keywords
- interferon lambda
- patient
- treatment
- hdv
- lambda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 168
- 108010050904 Interferons Proteins 0.000 title claims abstract description 168
- 229940079322 interferon Drugs 0.000 title claims abstract description 166
- 241000724709 Hepatitis delta virus Species 0.000 title claims abstract description 130
- 238000011282 treatment Methods 0.000 title claims description 114
- 230000009385 viral infection Effects 0.000 title description 2
- 208000037262 Hepatitis delta Diseases 0.000 claims abstract description 136
- 208000029570 hepatitis D virus infection Diseases 0.000 claims abstract description 134
- 208000015181 infectious disease Diseases 0.000 claims abstract description 37
- 230000003612 virological effect Effects 0.000 claims description 57
- 210000002966 serum Anatomy 0.000 claims description 55
- 230000009467 reduction Effects 0.000 claims description 32
- 230000006872 improvement Effects 0.000 claims description 19
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 16
- 108010082126 Alanine transaminase Proteins 0.000 claims description 16
- 208000019423 liver disease Diseases 0.000 claims description 14
- 230000003908 liver function Effects 0.000 claims description 14
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 11
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 10
- 230000000840 anti-viral effect Effects 0.000 claims description 10
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 claims description 6
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims description 6
- 102100027378 Prothrombin Human genes 0.000 claims description 5
- 108010094028 Prothrombin Proteins 0.000 claims description 5
- 102000007562 Serum Albumin Human genes 0.000 claims description 5
- 108010071390 Serum Albumin Proteins 0.000 claims description 5
- 229940039716 prothrombin Drugs 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 3
- 102100025255 Haptoglobin Human genes 0.000 claims description 3
- 108050005077 Haptoglobin Proteins 0.000 claims description 3
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 description 43
- 230000001684 chronic effect Effects 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 238000010254 subcutaneous injection Methods 0.000 description 19
- 239000007929 subcutaneous injection Substances 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 15
- 241000700721 Hepatitis B virus Species 0.000 description 14
- 108010047761 Interferon-alpha Proteins 0.000 description 13
- 102000006992 Interferon-alpha Human genes 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000037581 Persistent Infection Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 4
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 239000002777 nucleoside Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102100020990 Interferon lambda-1 Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical class 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001002469 Homo sapiens Interferon lambda-2 Proteins 0.000 description 2
- 108010054267 Interferon Receptors Proteins 0.000 description 2
- 102000001617 Interferon Receptors Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102100037971 Interferon lambda receptor 1 Human genes 0.000 description 2
- 101710099623 Interferon lambda-1 Proteins 0.000 description 2
- 102100020989 Interferon lambda-2 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 229950001750 lonafarnib Drugs 0.000 description 2
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 244000045410 Aegopodium podagraria Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 1
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 1
- 101000599613 Homo sapiens Interferon lambda receptor 1 Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101001002466 Homo sapiens Interferon lambda-3 Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 1
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100026688 Interferon epsilon Human genes 0.000 description 1
- 101710147309 Interferon epsilon Proteins 0.000 description 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 1
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 1
- 101710145151 Interferon lambda receptor 1 Proteins 0.000 description 1
- 102100020992 Interferon lambda-3 Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 1
- 101710199214 Interleukin-10 receptor subunit beta Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108050005735 Maltoporin Proteins 0.000 description 1
- 241000997826 Melanocetus johnsonii Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940121659 Prenyltransferase inhibitor Drugs 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102000042834 TEC family Human genes 0.000 description 1
- 108091082333 TEC family Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 108010085650 interferon gamma receptor Proteins 0.000 description 1
- 108010018844 interferon type III Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012045 magnetic resonance elastography Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002113 ultrasound elastography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009265 virologic response Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297759P | 2016-02-19 | 2016-02-19 | |
| PCT/US2017/018466 WO2017143253A1 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2874592T3 true ES2874592T3 (es) | 2021-11-05 |
Family
ID=59625481
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17753966T Active ES2874592T3 (es) | 2016-02-19 | 2017-02-17 | Tratamiento de la infección por el virus de la hepatitis delta con interferón lambda |
| ES21164362T Active ES3008560T3 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21164362T Active ES3008560T3 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953072B2 (https=) |
| EP (2) | EP3416675B9 (https=) |
| JP (3) | JP7674628B2 (https=) |
| KR (1) | KR20180110127A (https=) |
| CN (1) | CN108883156A (https=) |
| CY (1) | CY1124220T1 (https=) |
| DK (1) | DK3416675T3 (https=) |
| ES (2) | ES2874592T3 (https=) |
| HR (1) | HRP20210862T1 (https=) |
| HU (1) | HUE055343T2 (https=) |
| LT (1) | LT3416675T (https=) |
| PL (1) | PL3416675T3 (https=) |
| PT (1) | PT3416675T (https=) |
| RS (1) | RS61944B1 (https=) |
| SI (1) | SI3416675T1 (https=) |
| SM (1) | SMT202100335T1 (https=) |
| WO (1) | WO2017143253A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| JP7674628B2 (ja) | 2016-02-19 | 2025-05-12 | イーアイティー・ファーマ・インコーポレイテッド | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| GB201621728D0 (en) | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
| JP7571008B2 (ja) * | 2018-08-23 | 2024-10-22 | アイガー・バイオファーマシューティカルズ・インコーポレイテッド | インターフェロンラムダでのデルタ肝炎ウイルス感染処置 |
| EP3999101A1 (en) | 2019-07-18 | 2022-05-25 | ENYO Pharma | Method for decreasing adverse-effects of interferon |
| WO2021034101A1 (ko) * | 2019-08-21 | 2021-02-25 | 한국과학기술원 | 신규 인터페론 람다 변이체 및 이의 제조방법 |
| EP4045034A4 (en) * | 2019-10-16 | 2023-05-24 | Eiger Biopharmaceuticals, Inc. | METHODS OF TREATMENT OF HEPATITIS DELTA VIRUS INFECTIONS |
| EP4100047A4 (en) * | 2020-02-06 | 2024-03-13 | Eiger Biopharmaceuticals, Inc. | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60135393D1 (de) | 2000-06-30 | 2008-09-25 | Zymogenetics Inc | Allelische Variante des Interferon-ähnlichen Proteins Zcyto21 |
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| CA2503305A1 (en) | 2002-10-23 | 2004-05-06 | Zymogenetics, Inc. | Methods for treating viral infection using il-28 and il-29 |
| CA2520148A1 (en) | 2003-04-01 | 2004-12-23 | Intermune, Inc. | Compositions and methods for treating coronavirus infection and sars |
| EP2251352A1 (en) | 2003-08-07 | 2010-11-17 | ZymoGenetics, L.L.C. | Homogeneous preparations of IL-28 and IL-29 |
| JP4896005B2 (ja) | 2004-04-02 | 2012-03-14 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法 |
| WO2006076014A2 (en) | 2004-04-30 | 2006-07-20 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interferon-alpha constructs for use in the treatment of sars |
| AU2006272937A1 (en) | 2005-07-20 | 2007-02-01 | Bristol-Myers Squibb Company | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| EP1912668A2 (en) | 2005-07-20 | 2008-04-23 | ZymoGenetics, Inc. | Il28 and il29 truncated cysteine mutants and antiviral methods of using same |
| CA2625208A1 (en) | 2005-10-04 | 2007-04-12 | Zymogenetics, Inc. | Production and purification of il-29 |
| CN102886052B (zh) * | 2006-09-14 | 2014-07-30 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
| KR101652767B1 (ko) | 2008-04-04 | 2016-08-31 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Ｉｌ-28을 이용한 백신 및 면역치료제, 및 그를 사용하는 방법 및 조성물 |
| WO2011088126A2 (en) | 2010-01-13 | 2011-07-21 | Eiger Biopharmaceuticals, Inc. | Treatment of viral infection with prenyltransferase inhibitors |
| AU2012237295A1 (en) | 2011-04-01 | 2013-09-19 | Novartis Ag | Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases |
| CN103732250A (zh) * | 2011-06-14 | 2014-04-16 | 全球免疫股份有限公司 | 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法 |
| CA2846092A1 (en) | 2011-08-25 | 2013-02-28 | Nanogen Pharmaceutical Biotechnology | Peg-interferon lambda 1 conjugates |
| US8454947B1 (en) | 2012-03-01 | 2013-06-04 | Nanogen Pharmaceutical Biotechnology | PEG-interferon lambda 1 conjugates |
| SG11201501255PA (en) | 2012-08-30 | 2015-03-30 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
| TW201427664A (zh) | 2012-11-02 | 2014-07-16 | Pharmacyclics Inc | Ｔｅｃ家族激酶抑制劑佐劑療法 |
| PL3137078T3 (pl) * | 2014-05-01 | 2019-08-30 | Eiger Biopharmaceuticals, Inc. | Leczenie zakażenia wirusem zapalenia wątroby typu delta |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US20180338993A1 (en) | 2014-12-04 | 2018-11-29 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| EP3370723B1 (en) * | 2015-11-04 | 2020-12-16 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| JP7674628B2 (ja) | 2016-02-19 | 2025-05-12 | イーアイティー・ファーマ・インコーポレイテッド | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| GB201621728D0 (en) | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
| JP7571008B2 (ja) | 2018-08-23 | 2024-10-22 | アイガー・バイオファーマシューティカルズ・インコーポレイテッド | インターフェロンラムダでのデルタ肝炎ウイルス感染処置 |
| US20220387432A1 (en) | 2019-09-19 | 2022-12-08 | Eip Pharma, Inc. | Compositions and methods for treating prion disease |
| EP4100047A4 (en) | 2020-02-06 | 2024-03-13 | Eiger Biopharmaceuticals, Inc. | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA |
-
2017
- 2017-02-17 JP JP2018543599A patent/JP7674628B2/ja active Active
- 2017-02-17 HR HRP20210862TT patent/HRP20210862T1/hr unknown
- 2017-02-17 ES ES17753966T patent/ES2874592T3/es active Active
- 2017-02-17 EP EP17753966.5A patent/EP3416675B9/en active Active
- 2017-02-17 SI SI201730795T patent/SI3416675T1/sl unknown
- 2017-02-17 EP EP21164362.2A patent/EP3957319B1/en active Active
- 2017-02-17 CN CN201780020097.4A patent/CN108883156A/zh active Pending
- 2017-02-17 KR KR1020187026586A patent/KR20180110127A/ko not_active Ceased
- 2017-02-17 US US15/999,239 patent/US10953072B2/en active Active
- 2017-02-17 WO PCT/US2017/018466 patent/WO2017143253A1/en not_active Ceased
- 2017-02-17 PL PL17753966T patent/PL3416675T3/pl unknown
- 2017-02-17 DK DK17753966.5T patent/DK3416675T3/da active
- 2017-02-17 LT LTEP17753966.5T patent/LT3416675T/lt unknown
- 2017-02-17 PT PT177539665T patent/PT3416675T/pt unknown
- 2017-02-17 RS RS20210703A patent/RS61944B1/sr unknown
- 2017-02-17 SM SM20210335T patent/SMT202100335T1/it unknown
- 2017-02-17 ES ES21164362T patent/ES3008560T3/es active Active
- 2017-02-17 HU HUE17753966A patent/HUE055343T2/hu unknown
-
2021
- 2021-02-18 US US17/178,424 patent/US12508297B2/en active Active
- 2021-06-10 CY CY20211100511T patent/CY1124220T1/el unknown
-
2022
- 2022-09-02 JP JP2022140259A patent/JP2022172279A/ja active Pending
-
2024
- 2024-08-01 JP JP2024125792A patent/JP2024156840A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3416675B1 (en) | 2021-03-24 |
| KR20180110127A (ko) | 2018-10-08 |
| SMT202100335T1 (it) | 2021-07-12 |
| EP3416675A1 (en) | 2018-12-26 |
| US20210228686A1 (en) | 2021-07-29 |
| EP3416675A4 (en) | 2020-01-08 |
| HUE055343T2 (hu) | 2022-05-28 |
| US12508297B2 (en) | 2025-12-30 |
| HRP20210862T1 (hr) | 2021-09-17 |
| WO2017143253A1 (en) | 2017-08-24 |
| JP2022172279A (ja) | 2022-11-15 |
| JP7674628B2 (ja) | 2025-05-12 |
| JP2024156840A (ja) | 2024-11-06 |
| CN108883156A (zh) | 2018-11-23 |
| US10953072B2 (en) | 2021-03-23 |
| EP3957319A1 (en) | 2022-02-23 |
| PT3416675T (pt) | 2021-06-14 |
| RS61944B1 (sr) | 2021-07-30 |
| ES3008560T3 (en) | 2025-03-24 |
| EP3416675B9 (en) | 2021-07-14 |
| US20190111110A1 (en) | 2019-04-18 |
| SI3416675T1 (sl) | 2021-09-30 |
| CY1124220T1 (el) | 2022-05-27 |
| DK3416675T3 (da) | 2021-06-14 |
| EP3957319B1 (en) | 2024-12-04 |
| JP2019505553A (ja) | 2019-02-28 |
| PL3416675T3 (pl) | 2021-10-11 |
| LT3416675T (lt) | 2021-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2874592T3 (es) | Tratamiento de la infección por el virus de la hepatitis delta con interferón lambda | |
| Balistreri et al. | The safety and effectiveness of ledipasvir− sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection | |
| US20130109647A1 (en) | Methods and compositions for treating hepatitis c virus | |
| BR112021003204A2 (pt) | tratamento da infecção por vírus da hepatite delta com interferon lambda | |
| US20180110796A1 (en) | Compositions and methods for the treatment of hbv infection | |
| Jorns et al. | Rapid and simple detection of IFN‐neutralizing antibodies in chronic hepatitis C non‐responsive to IFN‐α | |
| WO2013066748A1 (en) | Methods and compositions for treating hepatitis c virus | |
| WO2011098644A2 (es) | Composiciones para el tratamiento de enfermedades infecciosas y tumorales | |
| EP4045034A1 (en) | Methods to treat hepatitis delta viral infections | |
| US20240108691A1 (en) | Treatment of hepatitis e virus infection with interferon lambda | |
| JPWO2004083186A1 (ja) | ウイルス性肝炎治療剤及び制癌剤 | |
| WO2024223797A1 (en) | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections | |
| Sato et al. | Delayed viral clearance after 6-week treatment with peginterferon plus ribavirin in a patient with chronic hepatitis C virus genotype 1b | |
| JP2013515682A (ja) | Ｃ型肝炎ウイルス阻害剤としての２’，２−ビスチアゾール非ヌクレオシド系化合物の医薬用途 | |
| Gupta et al. | Hepatitis-B: recent treatment | |
| OA19692A (en) | Combination therapies of hepatitis B virus (HBV)-infected individuals using Parapoxvirus ovis (PPVO) and at least one further antiviral drug. | |
| WO2013137869A1 (en) | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |